These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29765782)

  • 21. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study.
    Mageau A; Bonnotte B; Ebbo M; Dossier A; Galicier L; Souchaud-Debouverie O; Orvain C; Gerfaud-Valentin M; Gobert D; Riviere E; Audia S; Mahevas M; Michel M; Viallard JF; Godeau B
    Platelets; 2023 Dec; 34(1):2200848. PubMed ID: 37128870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
    Huizinga TWJ; Torii Y; Muniz R
    Rheumatol Ther; 2021 Mar; 8(1):41-61. PubMed ID: 33263165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biosimilars: what the dermatologist should know.
    Yamauchi P; Crowley J; Kaur P; Spelman L; Warren R
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1066-1074. PubMed ID: 29360210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rise of oncology biosimilars: from process to promise.
    Verrill M; Declerck P; Loibl S; Lee J; Cortes J
    Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
    Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
    BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilar biological drugs in the treatment of inflammatory bowel diseases.
    Kaniewska M; Eder P; Gąsiorowska A; Gonciarz M; Kierkuś J; Małecka-Panas E; Rydzewska G
    Prz Gastroenterol; 2019; 14(4):223-227. PubMed ID: 31988667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M; Wolff-Holz E
    Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars: Key regulatory considerations and similarity assessment tools.
    Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A
    Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
    MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
    Ludwig WD; Dicheva S
    Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.